Penumbra (PEN) to Release Quarterly Earnings on Wednesday

Key Points

• Penumbra will report Q1 2026 results after the market on April 22, 2026 at 4:30 PM ET; analysts expect $1.07 EPS and $372.04 million in revenue.
• In the prior quarter Penumbra missed EPS estimates (reported $(0.37) vs. $1.12 expected) but posted revenue of $385.4 million, up 22.2% year‑over‑year; analysts forecast roughly $4 EPS for the current fiscal year and $5 for next year.
• The stock trades with about a $13.0 billion market cap and a consensus Hold rating (average price target $361.69), while recent insider sales by the CFO and a director and high institutional ownership (~89%) are notable.

Penumbra (NYSE:PEN - Get Free Report) is anticipated to issue its Q1 2026 results after the market closes on Wednesday, April 22nd. Analysts expect the company to announce earnings of $1.07 per share and revenue of $372.0440 million for the quarter. Parties may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, April 22, 2026 at 4:30 PM ET.

Penumbra (NYSE:PEN - Get Free Report) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of $1.12 by ($1.49). The company had revenue of $385.39 million during the quarter, compared to analyst estimates of $367.18 million. Penumbra had a net margin of 12.66% and a return on equity of 11.41%. The firm's quarterly revenue was up 22.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.97 EPS. On average, analysts expect Penumbra to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Penumbra Stock Up 0.2%

Penumbra stock opened at $332.03 on Wednesday. The stock has a market capitalization of $13.03 billion, a PE ratio of 73.46, a price-to-earnings-growth ratio of 2.02 and a beta of 0.84. Penumbra has a twelve month low of $221.26 and a twelve month high of $362.41. The company has a quick ratio of 4.29, a current ratio of 6.64 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average of $336.62 and a 200-day moving average of $308.19.

Analyst Ratings Changes

PEN has been the subject of several research analyst reports. Truist Financial cut shares of Penumbra from a "buy" rating to a "hold" rating and upped their price target for the company from $370.00 to $374.00 in a report on Friday, January 16th. JPMorgan Chase & Co. upgraded shares of Penumbra from a "neutral" rating to an "overweight" rating and upped their price target for the company from $275.00 to $370.00 in a report on Thursday, December 18th. Piper Sandler cut shares of Penumbra from an "overweight" rating to a "hold" rating and set a $374.00 price target for the company. in a report on Thursday, January 15th. Royal Bank Of Canada cut shares of Penumbra from an "outperform" rating to a "sector perform" rating and upped their price target for the company from $355.00 to $374.00 in a report on Tuesday, January 20th. Finally, Wall Street Zen cut shares of Penumbra from a "buy" rating to a "hold" rating in a report on Saturday, January 17th. Four analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $361.69.

Insider Buying and Selling at Penumbra

In related news, Director Harpreet Grewal sold 100 shares of the stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $328.22, for a total transaction of $32,822.00. Following the completion of the transaction, the director owned 8,719 shares in the company, valued at approximately $2,861,750.18. This represents a 1.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Maggie Yuen sold 2,432 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $342.30, for a total transaction of $832,473.60. Following the transaction, the chief financial officer owned 18,353 shares of the company's stock, valued at $6,282,231.90. The trade was a 11.70% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 5.00% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. CIBC Private Wealth Group LLC boosted its holdings in Penumbra by 2,700.0% during the fourth quarter. CIBC Private Wealth Group LLC now owns 84 shares of the company's stock worth $26,000 after purchasing an additional 81 shares during the last quarter. Motiv8 Investments LLC acquired a new stake in Penumbra in the fourth quarter valued at $27,000. State of Wyoming acquired a new stake in Penumbra in the second quarter valued at $64,000. Itau Unibanco Holding S.A. acquired a new stake in Penumbra in the fourth quarter valued at $64,000. Finally, EverSource Wealth Advisors LLC lifted its stake in Penumbra by 209.1% in the second quarter. EverSource Wealth Advisors LLC now owns 272 shares of the company's stock valued at $70,000 after acquiring an additional 184 shares during the last quarter. Institutional investors and hedge funds own 88.88% of the company's stock.

Penumbra Company Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra's technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra's portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.